Dose-Escalation Study of Thoracic Radiotherapy in Combination With Pemetrexed Plus Cisplatin Followed by Pemetrexed Consolidation Therapy in Japanese Patients With Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer

Seiji Niho(Dokkyo Medical University), Tomohide Tamura(St. Luke's International Hospital), Keiji Nihei(Osaka Medical and Pharmaceutical University), Ikuo Sekine(University of Tsukuba), Jumpei Funai(Eli Lilly (Japan)), Yuichiro Ohe(National Cancer Center), Kaoru Kubota(Nippon Medical School Hospital), Sotaro Enatsu(Eli Lilly (Japan)), Risa Sekiguchi(Eli Lilly (Japan)), Minako Sumi(Tokyo Metropolitan Geriatric Hospital)
Clinical Lung Cancer
May 24, 2012
10.1016/j.cllc.2012.03.007
Cited by 16

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
|British Journal of Cancer|2010|749